AstraZeneca (LON:AZN) Given "Buy" Rating at Shore Capital

Key Points

• AstraZeneca received a "Buy" rating from Shore Capital, with a target price of £145, suggesting a potential upside of 13.35% from its previous close.
• Other analysts have mixed opinions, with Deutsche Bank maintaining a "Hold" rating at £110 and Berenberg Bank reiterating a "Buy" rating at £142, leading to a consensus rating of "Moderate Buy."
• AstraZeneca's share price was £127.92 following an increase during trading, with a market capitalization of £198.31 billion and a notable 1-year trading range.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "buy" rating restated by Shore Capital in a research note issued on Tuesday,Digital Look reports. They currently have a £145 target price on the biopharmaceutical company's stock. Shore Capital's price objective indicates a potential upside of 13.35% from the company's previous close.

Other analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a £110 price target on shares of AstraZeneca in a research report on Wednesday, July 30th. Berenberg Bank reiterated a "buy" rating and set a £142 price objective on shares of AstraZeneca in a research report on Monday, September 1st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of "Moderate Buy" and an average price target of £134.25.

AstraZeneca Stock Performance

Shares of LON:AZN traded up GBX 66 during trading hours on Tuesday, hitting £127.92. The stock had a trading volume of 24,580,590 shares, compared to its average volume of 9,140,370. AstraZeneca has a 1-year low of GBX 9,573.51 and a 1-year high of £128.66. The firm has a market capitalization of £198.31 billion, a price-to-earnings ratio of 2,409.04, a PEG ratio of 0.86 and a beta of 0.17. The stock's fifty day simple moving average is £116.23 and its 200 day simple moving average is £108.99. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

Insider Activity at AstraZeneca

In other news, insider Aradhana Sarin sold 9,563 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of £115.12, for a total value of £1,100,892.56. Corporate insiders own 0.14% of the company's stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.